Join to View Full Profile
16620 San Pedro AveSte 300San Antonio, TX 78232
Dr. Pergola is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Pablo Pergola is a nephrologist based in San Antonio, TX, with a robust educational background from the University of Texas Health Science Center San Antonio, where he completed his residency in internal medicine and fellowship in nephrology. He has experience in areas such as chronic kidney disease, diabetic nephropathy, bone mineral disease, and anemia in CKD. Dr. Pergola has contributed to several publications in reputable journals and has been involved in multiple clinical trials, emphasizing his research in nephrology.
Education & Training
University of Texas Health Science Center San Antonio Joe and Teresa Lozano Long School of MedicineFellowship, Nephrology, 1997 - 1999- University of Texas Health Science Center San Antonio Joe and Teresa Lozano Long School of MedicineResidency, Internal Medicine, 1994 - 1997
Univ Salvador- Fac MedClass of 1988
Certifications & Licensure
TX State Medical License 1998 - 2026
American Board of Internal Medicine Nephrology
National Board of Physicians and Surgeons Internal Medicine- National Board of Physicians and Surgeons Nephrology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification eClinicalWorks, eClinicalWorks, LLC, 2012, 2014
- CMS Meaningful Use Stage 1 Certification eClinicalWorks EHR, eClinicalWorks LLC, 2012-2013
Clinical Trials
- Hyponatremia Registry for Patients With Euvolemic and Hypervolemic Hyponatremia Start of enrollment: 2010 Sep 01
- Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis
- A Phase 2/3 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients With Alport Syndrome - CARDINAL Start of enrollment: 2017 Mar 02
Publications & Presentations
PubMed
- Finerenone in Patients With Chronic Kidney Disease Due to Glomerular Diseases: A Randomized Clinical Trial.Brendon L Neuen, Vlado Perkovic, Rajiv Agarwal, David Z I Cherney, Carolyn S P Lam
JAMA. 2026-06-05 - Chronic Inflammation as an Overlooked Link between Cardiovascular and Kidney Disease: A Focus on IL-6 and C-Reactive Protein.Pablo Pergola, Richard J Johnson, Adeera Levin, Peter Stenvinkel
Clinical Journal of the American Society of Nephrology. 2026-03-10 - 8 citationsBalcinrenone in combination with dapagliflozin compared with dapagliflozin alone in patients with chronic kidney disease and albuminuria: a randomised, active-controll...Hiddo J L Heerspink, José F Cardona, Shivinder Jolly, Pablo E Pergola, Erika de Sousa-Amorim
Lancet. 2025-11-22
Press Mentions
Unicycive Presents New Patient-Level Data Underscoring Challenges Faced with Current Phosphate Binders and Highlighting the Potential of Oxylanthanum Carbonate to Address Barriers to Adherence for Patients with Hyperphosphatemia on DialysisApril 10th, 2025- KIND Presents Positive Results of AND017 to Treat Anemia Associated with Chronic Kidney Disease in Two Phase II and Two Phase IOctober 28th, 2024
Reata Pharma Shares Trading Higher After Reacquiring U.S. And Worldwide Licensing RightsOctober 14th, 2019
Other Languages
- Spanish
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
